Chester County News and Community Website
Ocugen, Inc. (NASDAQ: OCGN), headquartered in Malvern, PA, is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. Their breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and their novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. For more information, visit www.ocugen.com.
MALVERN, PA — On Friday, Ocugen (Nasdaq: OCGN) closed a $22.5 million registered direct stock offering, strengthening its balance sheet as the gene-therapy developer pushes forward with programs targeting blinding …
Ocugen Raises $20.9M to Extend Cash Runway Into Late 2026 Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) said preliminary 12-month data from its Phase 2 ArMaDa clinical trial showed meaningful reductions in disease progression for patients with geographic atrophy, a …
Ocugen (NASDAQ: OCGN) Reports Strong Midstage Data for Gene Therapy Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) said newly published clinical trial data support the safety and early effectiveness of its experimental gene therapy for Stargardt disease, a rare inherited …
Gene Therapy Slows Vision Loss in Stargardt Trial, Fueling Hope for First Treatment Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) is stepping into one of biotech’s most important global spotlights, with its top executive set to present the company’s gene therapy strategy at …
Ocugen Eyes a Breakout Year as It Takes Center Stage at JPM Healthcare Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) will present its latest advances in gene therapy for blindness diseases at NobleCon21, the annual emerging growth equity conference hosted by Noble Capital …
Ocugen CEO to Spotlight Gene Therapy Breakthroughs at High-Profile Growth Conference Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) reported third-quarter 2025 financial results and provided an update on its advancing portfolio of late-stage gene therapies for inherited retinal diseases. The biotechnology …
Ocugen Advances Gene Therapy Pipeline as Phase 3 Trials Near Key Milestones Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced it will release its third-quarter 2025 financial results before the market opens on Wednesday, November 5, 2025, followed by a conference call …
Ocugen to Announce Third-Quarter 2025 Results and Business Update on November 5 Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced that its leadership team will present at three upcoming industry and investor events: the 2025 Cell & Gene Meeting on the Mesa, …
Ocugen to Highlight Gene Therapy Pipeline at Key Industry and Investor Conferences Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has signed an exclusive licensing agreement with South Korea’s Kwangdong Pharmaceutical Co., Ltd. for the rights to commercialize OCU400, its experimental modifier gene …
Ocugen Strikes $7.5 Million Licensing Deal With Kwangdong for Gene Therapy in Korea Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has signed an exclusive licensing agreement with South Korea’s Kwangdong Pharmaceutical Co., Ltd. for the rights to develop and commercialize OCU400, Ocugen’s experimental …
Ocugen Strikes $187.5 Million Licensing Deal With Kwangdong for Gene Therapy in Korea Read More